Open Health has joined forces with health economics and outcomes research (HEOR) company Pharmerit International in a move that strengthens its existing market access capabilities.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh